Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".
作者信息
Gedallovich Seren M, Kwo Paul Y
机构信息
Division of Gastroenterology and Hepatology, Stanford University Medical School, Stanford, CA, USA.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):677-681. doi: 10.3350/cmh.2024.0418. Epub 2024 Jun 11.
Abstract
摘要
相似文献
1
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".
Clin Mol Hepatol. 2024 Oct;30(4):677-681. doi: 10.3350/cmh.2024.0418. Epub 2024 Jun 11.
2
Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".
Clin Mol Hepatol. 2024 Oct;30(4):1023-1025. doi: 10.3350/cmh.2024.0472. Epub 2024 Jul 1.
3
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.
Clin Mol Hepatol. 2024 Jul;30(3):326-344. doi: 10.3350/cmh.2024.0155. Epub 2024 Apr 26.
4
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
5
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.
Clin Mol Hepatol. 2020 Jul;26(3):251-260. doi: 10.3350/cmh.2020.0018. Epub 2020 Mar 19.
6
Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Hepatobiliary Pancreat Dis Int. 2020 Dec;19(6):541-546. doi: 10.1016/j.hbpd.2020.06.013. Epub 2020 Jun 30.
7
AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Gastroenterology. 2019 Jun;156(8):2149-2157. doi: 10.1053/j.gastro.2019.02.046. Epub 2019 Mar 13.
8
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
World J Gastroenterol. 2019 Aug 7;25(29):3929-3940. doi: 10.3748/wjg.v25.i29.3929.
9
Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
J Viral Hepat. 2022 Jan;29(1):35-42. doi: 10.1111/jvh.13625. Epub 2021 Oct 27.
10
Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
World J Gastroenterol. 2022 Jan 7;28(1):140-153. doi: 10.3748/wjg.v28.i1.140.
本文引用的文献
1
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.
Liver Cancer. 2024 Feb 12;13(5):468-486. doi: 10.1159/000537686. eCollection 2024 Oct.
2
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.
Clin Mol Hepatol. 2024 Jul;30(3):326-344. doi: 10.3350/cmh.2024.0155. Epub 2024 Apr 26.
3
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.
Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. doi: 10.1038/s41571-023-00825-3. Epub 2023 Oct 26.
4
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3.
5
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
Hepatology. 2025 Mar 1;81(3):1038-1057. doi: 10.1097/HEP.0000000000000513. Epub 2023 Jun 12.
6
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
7
The Prognostic Value of AT-Rich Interaction Domain (ARID) Family Members in Patients with Hepatocellular Carcinoma.
Evid Based Complement Alternat Med. 2022 Aug 18;2022:1150390. doi: 10.1155/2022/1150390. eCollection 2022.
8
Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation.
Cancers (Basel). 2022 Jun 21;14(13):3036. doi: 10.3390/cancers14133036.
9
NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population.
Hepatol Commun. 2022 Sep;6(9):2310-2321. doi: 10.1002/hep4.1976. Epub 2022 May 3.
10
HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.
Hepatology. 2022 Jul;76(1):139-154. doi: 10.1002/hep.32341. Epub 2022 Feb 7.
Zotero 插件